News and Press Releases

Contact Veristat Now

Request A Proposal

Contact Us

Veristat and Molecular Templates Inc. enter into Preferred Provider Agreement for Refractory non-Hodgkin’s B-Cell Lymphoma trial

For Immediate Release

Read More

Veristat to Assist on Adaptive Enrichment Design Trial for Verastem’s Defactinib in Mesothelioma

Input Will Drive Trial Design for Lead Cancer Stem Cell-Targeting Program

 

September 10, 2013  -  Veristat, a leading, Boston-based clinical research organization today announced its advisory role on the implementation of an adaptive enrichment trial design for Verastem, Inc. (NASDAQ: VSTM).

Read More

Veristat’s Collaboration with Aegerion Contributes to FDA Approval of Juxtapid™

Veristat’s Strategic Guidance Contributes to Successful Approval of Aegerion’s Novel Drug Juxtapid

 

Read More

Variance Development Partners Makes a Growth Investment in Veristat

Investment Will Enable Veristat to Further Enhance its Market Leadership Position and Provide Resources for Growth

Veristat, a leading Clinical Research Organization (CRO) announced today that Variance Development Partners, a private investment group focused on contributing growth capital to small to mid-sized firms providing services to developing pharmaceutical and medical device companies, has made a growth equity investment in the company.

Read More

Search

    Topics

    see all

    Follow Us

    Monthly Archives

    see all
    • Privacy Policy
    • ©2006 - 2021 Veristat, LLC. All rights reserved. Veristat is a trademark of Veristat, LLC. All other trademarks are the property of their respective owners.